Skip to main content
SpringerLink
Log in

Rapid Intermittent Involuntary Movements

  • Chapter
  • First Online:
Book cover Disorders of Movement

  • 1823 Accesses

Abstract

Within the rubric of involuntary movements, we recognize two types, myoclonus and chorea, which should be distinguished from every other abnormal movement for being, by definition, very brief, non-rhythmical and variable for frequency and severity of presentation. Myoclonus and chorea are both characterized by a remarkably broad array of possible underlying aetiologies, and their diagnostic work-up is one of the most complex in the whole field of disorders of movement. Given this complexity, this section is divided in two separate parts, which provide a guide to the phenomenological recognition, differential diagnosis and treatment of myoclonus (Part A) and chorea (Part B).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Salazar G, Valls-Sole J, Marti MJ, Chang H, Tolosa ES. Postural and action myoclonus in patients with parkinsonian type multiple system atrophy. Mov Disord. 2000;15:77–83.

    Article  CAS  PubMed  Google Scholar 

  2. Carr J. Classifying myoclonus: a riddle, wrapped in a mystery, inside an enigma. Parkinsonism Relat Disord. 2012;18 Suppl 1:S174–6.

    Article  PubMed  Google Scholar 

  3. Espay AJ, Chen R. Myoclonus. Continuum (Minneap Minn). 2013;19:1264–86.

    Google Scholar 

  4. Hallett M, Chadwick D, Adam J, Marsden CD. Reticular reflex myoclonus: a physiological type of human post-hypoxic myoclonus. J Neurol Neurosurg Psychiatry. 1977;40:253–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Esposito M, Edwards MJ, Bhatia KP, Brown P, Cordivari C. Idiopathic spinal myoclonus: a clinical and neurophysiological assessment of a movement disorder of uncertain origin. Mov Disord. 2009;24:2344–9.

    PubMed  Google Scholar 

  6. Roze E, Bounolleau P, Ducreux D, Cochen V, Leu-Semenescu S, Beaugendre Y, Lavallard-Rousseau MC, Blancher A, Bourdain F, Dupont P, Carluer L, Verdure L, Vidailhet M, Apartis E. Propriospinal myoclonus revisited: clinical, neurophysiologic, and neuroradiologic findings. Neurology. 2009;72:1301–9.

    Article  CAS  PubMed  Google Scholar 

  7. van der Salm SM, Koelman JH, Henneke S, van Rootselaar AF, Tijssen MA. Axial jerks: a clinical spectrum ranging from propriospinal to psychogenic myoclonus. J Neurol. 2010;257:1349–55.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Espay AJ, Ashby P, Hanajima R, Jog MS, Lang AE. Unique form of propriospinal myoclonus as a possible complication of an enteropathogenic toxin. Mov Disord. 2003;18:942–8.

    Article  PubMed  Google Scholar 

  9. Glass GA, Ahlskog JE, Matsumoto JY. Orthostatic myoclonus: a contributor to gait decline in selected elderly. Neurology. 2007;68:1826–30.

    Article  PubMed  Google Scholar 

  10. Espay AJ, Lang AE. Common movement disorders pitfalls: case-based teaching. New York: Cambridge University Press; 2012.

    Google Scholar 

  11. Leu-Semenescu S, Roze E, Vidailhet M, Legrand AP, Trocello JM, Cochen V, Sangla S, Apartis E. Myoclonus or tremor in orthostatism: an under-recognized cause of unsteadiness in Parkinson’s disease. Mov Disord. 2007;22:2063–9.

    Article  PubMed  Google Scholar 

  12. Koukouni V, Valente EM, Cordivari C, Bhatia KP, Quinn NP. Unusual familial presentation of epsilon-sarcoglycan gene mutation with falls and writer’s cramp. Mov Disord. 2008;23:1913–5.

    Article  PubMed  Google Scholar 

  13. Peall KJ, Kurian MA, Wardle M, Waite AJ, Hedderly T, Lin JP, Smith M, Whone A, Pall H, White C, Lux A, Jardine PE, Lynch B, Kirov G, O'Riordan S, Samuel M, Lynch T, King MD, Chinnery PF, Warner TT, Blake DJ, Owen MJ, Morris HR. SGCE and myoclonus dystonia: motor characteristics, diagnostic criteria and clinical predictors of genotype. J Neurol. 2014;261:2296–304.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Hess CW, Raymond D, Aguiar Pde C, Frucht S, Shriberg J, Heiman GA, Kurlan R, Klein C, Bressman SB, Ozelius LJ, Saunders-Pullman R. Myoclonus-dystonia, obsessive-compulsive disorder, and alcohol dependence in SGCE mutation carriers. Neurology. 2007;68:522–4.

    Article  CAS  PubMed  Google Scholar 

  15. Kinugawa K, Vidailhet M, Clot F, Apartis E, Grabli D, Roze E. Myoclonus-dystonia: an update. Mov Disord. 2009;24:479–89.

    Article  PubMed  Google Scholar 

  16. Zimprich A, Grabowski M, Asmus F, Naumann M, Berg D, Bertram M, Scheidtmann K, Kern P, Winkelmann J, Muller-Myhsok B, Riedel L, Bauer M, Muller T, Castro M, Meitinger T, Strom TM, Gasser T. Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet. 2001;29:66–9.

    Article  CAS  PubMed  Google Scholar 

  17. Peall KJ, Waite AJ, Blake DJ, Owen MJ, Morris HR. Psychiatric disorders, myoclonus dystonia, and the epsilon-sarcoglycan gene: a systematic review. Mov Disord. 2011;26:1939–42.

    Article  PubMed  Google Scholar 

  18. Bonello M, Larner AJ, Alusi SH. Myoclonus-dystonia (DYT11) with novel SGCE mutation misdiagnosed as a primary psychiatric disorder. J Neurol Sci. 2014;346:356–7.

    Article  CAS  PubMed  Google Scholar 

  19. Groen JL, Ritz K, Jalalzadeh H, van der Salm SM, Jongejan A, Mook OR, Haagmans MA, Zwinderman AH, Motazacker MM, Hennekam RC, Baas F, Tijssen MA. RELN rare variants in myoclonus-dystonia. Mov Disord. 2015;30:415–9.

    Article  CAS  PubMed  Google Scholar 

  20. Han F, Racacho L, Lang AE, Bulman DE, Grimes DA. Refinement of the DYT15 locus in myoclonus dystonia. Mov Disord. 2007;22:888–92.

    Article  PubMed  Google Scholar 

  21. Mencacci NE, R’Bibo L, Bandres-Ciga S, Carecchio M, Zorzi G, Nardocci N, Garavaglia B, Batla A, Bhatia KP, Pittman AM, Hardy J, Weissbach A, Klein C, Gasser T, Lohmann E, Wood NW. The CACNA1B R1389H variant is not associated with myoclonus-dystonia in a large European multicentric cohort. Hum Mol Genet. 2015;24:5326–9.

    Google Scholar 

  22. Kabakci K, Hedrich K, Leung JC, Mitterer M, Vieregge P, Lencer R, Hagenah J, Garrels J, Witt K, Klostermann F, Svetel M, Friedman J, Kostic V, Bressman SB, Breakefield XO, Ozelius LJ, Pramstaller PP, Klein C. Mutations in DYT1: extension of the phenotypic and mutational spectrum. Neurology. 2004;62:395–400.

    Article  CAS  PubMed  Google Scholar 

  23. Gatto EM, Pardal MM, Micheli FE. Unusual phenotypic expression of the DYT1 mutation. Parkinsonism Relat Disord. 2003;9:277–9.

    Article  PubMed  Google Scholar 

  24. Mencacci NE, Rubio-Agusti I, Zdebik A, Asmus F, Ludtmann MH, Ryten M, Plagnol V, Hauser AK, Bandres-Ciga S, Bettencourt C, Forabosco P, Hughes D, Soutar MM, Peall K, Morris HR, Trabzuni D, Tekman M, Stanescu HC, Kleta R, Carecchio M, Zorzi G, Nardocci N, Garavaglia B, Lohmann E, Weissbach A, Klein C, Hardy J, Pittman AM, Foltynie T, Abramov AY, Gasser T, Bhatia KP, Wood NW. A missense mutation in KCTD17 causes autosomal dominant myoclonus-dystonia. Am J Hum Genet. 2015;96:938–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Stamelou M, Mencacci NE, Cordivari C, Batla A, Wood NW, Houlden H, Hardy J, Bhatia KP. Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency. Neurology. 2012;79:435–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Leuzzi V, Carducci C, Carducci C, Cardona F, Artiola C, Antonozzi I. Autosomal dominant GTP-CH deficiency presenting as a dopa-responsive myoclonus-dystonia syndrome. Neurology. 2002;59:1241–3.

    Article  CAS  PubMed  Google Scholar 

  27. Luciano MS, Ozelius L, Sims K, Raymond D, Liu L, Saunders-Pullman R. Responsiveness to levodopa in epsilon-sarcoglycan deletions. Mov Disord. 2009;24:425–8.

    Article  PubMed  Google Scholar 

  28. Cilia R, Reale C, Castagna A, Nasca A, Muzi-Falconi M, Barzaghi C, Marzegan A, Granata M, Marotta G, Sacilotto G, Vallauri D, Pezzoli G, Goldwurm S, Garavaglia B. Novel DYT11 gene mutation in patients without dopaminergic deficit (SWEDD) screened for dystonia. Neurology. 2014;83:1155–62.

    Article  CAS  PubMed  Google Scholar 

  29. Groen JL, Andrade A, Ritz K, Jalalzadeh H, Haagmans M, Bradley TE, Jongejan A, Verbeek DS, Nurnberg P, Denome S, Hennekam RC, Lipscombe D, Baas F, Tijssen MA. CACNA1B mutation is linked to unique myoclonus-dystonia syndrome. Hum Mol Genet. 2015;24:987–93.

    Article  CAS  PubMed  Google Scholar 

  30. Guettard E, Portnoi MF, Lohmann-Hedrich K, Keren B, Rossignol S, Winkler S, El Kamel I, Leu S, Apartis E, Vidailhet M, Klein C, Roze E. Myoclonus-dystonia due to maternal uniparental disomy. Arch Neurol. 2008;65:1380–5.

    Article  PubMed  Google Scholar 

  31. Harper SJ, Wilkes RG. Posthypoxic myoclonus (the Lance-Adams syndrome) in the intensive care unit. Anaesthesia. 1991;46:199–201.

    Article  CAS  PubMed  Google Scholar 

  32. Shin JH, Park JM, Kim AR, Shin HS, Lee ES, Oh MK, Yoon CH. Lance-adams syndrome. Ann Rehabil Med. 2012;36:561–4.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Stein R, Canny GJ, Bohn DJ, Reisman JJ, Levison H. Severe acute asthma in a pediatric intensive care unit: six years’ experience. Pediatrics. 1989;83:1023–8.

    CAS  PubMed  Google Scholar 

  34. Paine MG, Che D, Li L, Neumar RW. Cerebellar Purkinje cell neurodegeneration after cardiac arrest: effect of therapeutic hypothermia. Resuscitation. 2012;83:1511–6.

    Article  PubMed  Google Scholar 

  35. Matsunaga K, Uozumi T, Qingrui L, Hashimoto T, Tsuji S. Amantadine-induced cortical myoclonus. Neurology. 2001;56:279–80.

    Article  CAS  PubMed  Google Scholar 

  36. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol. 2000;47:S2–9; discussion S9–11.

    Article  CAS  PubMed  Google Scholar 

  37. Gupta A, Lang AE. Drug-induced cranial myoclonus. Mov Disord. 2010;25:2264–5.

    Article  PubMed  Google Scholar 

  38. Pfeiffer RF. Amantadine-induced “vocal” myoclonus. Mov Disord. 1996;11:104–6.

    Article  CAS  PubMed  Google Scholar 

  39. Okuma Y, Fujishima K, Miwa H, Mori H, Mizuno Y. Myoclonic tremulous movements in multiple system atrophy are a form of cortical myoclonus. Mov Disord. 2005;20:451–6.

    Article  PubMed  Google Scholar 

  40. Hu WT, Rippon GW, Boeve BF, Knopman DS, Petersen RC, Parisi JE, Josephs KA. Alzheimer’s disease and corticobasal degeneration presenting as corticobasal syndrome. Mov Disord. 2009;24:1375–9.

    Article  PubMed  Google Scholar 

  41. Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, Boxer AL, Dickson DW, Grossman M, Hallett M, Josephs KA, Kertesz A, Lee SE, Miller BL, Reich SG, Riley DE, Tolosa E, Troster AI, Vidailhet M, Weiner WJ. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496–503.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Klaas JP, Ahlskog JE, Pittock SJ, Matsumoto JY, Aksamit AJ, Bartleson JD, Kumar R, McEvoy KF, McKeon A. Adult-onset opsoclonus-myoclonus syndrome. Arch Neurol. 2012;69:1598–607.

    Article  PubMed  Google Scholar 

  43. Blaes F, Fuhlhuber V, Korfei M, Tschernatsch M, Behnisch W, Rostasy K, Hero B, Kaps M, Preissner KT. Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann Neurol. 2005;58:313–7.

    Article  CAS  PubMed  Google Scholar 

  44. Franceschetti S, Michelucci R, Canafoglia L, Striano P, Gambardella A, Magaudda A, Tinuper P, La Neve A, Ferlazzo E, Gobbi G, Giallonardo AT, Capovilla G, Visani E, Panzica F, Avanzini G, Tassinari CA, Bianchi A, Zara F, Collaborative LsgoP. Progressive myoclonic epilepsies: definitive and still undetermined causes. Neurology. 2014;82:405–11.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Girard JM, Turnbull J, Ramachandran N, Minassian BA. Progressive myoclonus epilepsy. Handb Clin Neurol. 2013;113:1731–6.

    Article  PubMed  Google Scholar 

  46. Goldstein DS, Sharabi Y, Karp BI, Bentho O, Saleem A, Pacak K, Eisenhofer G. Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Clin Auton Res. 2007;17:118–21.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Czarnecki K, Hallett M. Functional (psychogenic) movement disorders. Curr Opin Neurol. 2012;25:507–12.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Mavridis M, Degryse AD, Lategan AJ, Marien MR, Colpaert FC. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson’s disease. Neuroscience. 1991;41:507–23.

    Article  CAS  PubMed  Google Scholar 

  49. Ramachandran N, Girard JM, Turnbull J, Minassian BA. The autosomal recessively inherited progressive myoclonus epilepsies and their genes. Epilepsia. 2009;50 Suppl 5:29–36.

    Article  CAS  PubMed  Google Scholar 

  50. Vaamonde J, Muruzabal J, Tunon T, Perez N, Artieda J, Rodriguez M, Obeso JA. Abnormal muscle and skin mitochondria in family with myoclonus, ataxia, and deafness (May and White syndrome). J Neurol Neurosurg Psychiatry. 1992;55:128–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Pezzella M, Yeghiazaryan NS, Veggiotti P, Bettinelli A, Giudizioso G, Zara F, Striano P, Minetti C. Galloway-Mowat syndrome: an early-onset progressive encephalopathy with intractable epilepsy associated to renal impairment. Two novel cases and review of literature. Seizure. 2010;19:132–5.

    Article  PubMed  Google Scholar 

  52. Rubboli G, Franceschetti S, Berkovic SF, Canafoglia L, Gambardella A, Dibbens LM, Riguzzi P, Campieri C, Magaudda A, Tassinari CA, Michelucci R. Clinical and neurophysiologic features of progressive myoclonus epilepsy without renal failure caused by SCARB2 mutations. Epilepsia. 2011;52:2356–63.

    Article  CAS  PubMed  Google Scholar 

  53. Dibbens LM, Michelucci R, Gambardella A, Andermann F, Rubboli G, Bayly MA, Joensuu T, Vears DF, Franceschetti S, Canafoglia L, Wallace R, Bassuk AG, Power DA, Tassinari CA, Andermann E, Lehesjoki AE, Berkovic SF. SCARB2 mutations in progressive myoclonus epilepsy (PME) without renal failure. Ann Neurol. 2009;66:532–6.

    Article  CAS  PubMed  Google Scholar 

  54. Fu YJ, Aida I, Tada M, Tada M, Toyoshima Y, Takeda S, Nakajima T, Naito H, Nishizawa M, Onodera O, Kakita A, Takahashi H. Progressive myoclonus epilepsy: extraneuronal brown pigment deposition and system neurodegeneration in the brains of Japanese patients with novel SCARB2 mutations. Neuropathol Appl Neurobiol. 2014;40:551–63.

    Article  CAS  PubMed  Google Scholar 

  55. Zhou L, Chillag KL, Nigro MA. Hyperekplexia: a treatable neurogenetic disease. Brain Dev. 2002;24:669–74.

    Article  PubMed  Google Scholar 

  56. Andrew M, Owen MJ. Hyperekplexia: abnormal startle response due to glycine receptor mutations. Br J Psychiatry. 1997;170:106–8.

    Article  CAS  PubMed  Google Scholar 

  57. Brown P. Neurophysiology of the startle syndrome and hyperekplexia. Adv Neurol. 2002;89:153–9.

    PubMed  Google Scholar 

  58. McKeon A, Martinez-Hernandez E, Lancaster E, Matsumoto JY, Harvey RJ, McEvoy KM, Pittock SJ, Lennon VA, Dalmau J. Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol. 2013;70:44–50.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Bode A, Lynch JW. The impact of human hyperekplexia mutations on glycine receptor structure and function. Mol Brain. 2014;7:2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Tijssen MA, Vergouwe MN, van Dijk JG, Rees M, Frants RR, Brown P. Major and minor form of hereditary hyperekplexia. Mov Disord. 2002;17:826–30.

    Article  PubMed  Google Scholar 

  61. James VM, Bode A, Chung SK, Gill JL, Nielsen M, Cowan FM, Vujic M, Thomas RH, Rees MI, Harvey K, Keramidas A, Topf M, Ginjaar I, Lynch JW, Harvey RJ. Novel missense mutations in the glycine receptor beta subunit gene (GLRB) in startle disease. Neurobiol Dis. 2012;52:137–49.

    Article  CAS  PubMed  Google Scholar 

  62. Carta E, Chung SK, James VM, Robinson A, Gill JL, Remy N, Vanbellinghen JF, Drew CJ, Cagdas S, Cameron D, Cowan FM, Del Toro M, Graham GE, Manzur AY, Masri A, Rivera S, Scalais E, Shiang R, Sinclair K, Stuart CA, Tijssen MA, Wise G, Zuberi SM, Harvey K, Pearce BR, Topf M, Thomas RH, Supplisson S, Rees MI, Harvey RJ. Mutations in the GlyT2 gene (SLC6A5) are a second major cause of startle disease. J Biol Chem. 2012;287:28975–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Tanner CM, Chamberland J. Latah in Jakarta, Indonesia. Mov Disord. 2001;16:526–9.

    Article  CAS  PubMed  Google Scholar 

  64. Saint-Hilaire MH, Saint-Hilaire JM, Granger L. Jumping Frenchmen of Maine. Neurology. 1986;36:1269–71.

    Article  CAS  PubMed  Google Scholar 

  65. McFarling DA. The “Ragin’ Cajuns” of Louisiana. Mov Disord. 2001;16:531–2.

    Article  CAS  PubMed  Google Scholar 

  66. Brown P, Ridding MC, Werhahn KJ, Rothwell JC, Marsden CD. Abnormalities of the balance between inhibition and excitation in the motor cortex of patients with cortical myoclonus. Brain. 1996;119(Pt 1):309–17.

    Article  PubMed  Google Scholar 

  67. Danner N, Saisanen L, Maatta S, Julkunen P, Hukkanen T, Kononen M, Hypponen J, Kalviainen R, Mervaala E. Motor cortical plasticity is impaired in Unverricht-Lundborg disease. Mov Disord. 2011;26:2095–100.

    Article  PubMed  Google Scholar 

  68. Chen R, Ashby P, Lang AE. Stimulus-sensitive myoclonus in akinetic-rigid syndromes. Brain. 1992;115(Pt 6):1875–88.

    Article  PubMed  Google Scholar 

  69. Ganos C, Kassavetis P, Erro R, Edwards MJ, Rothwell J, Bhatia KP. The role of the cerebellum in the pathogenesis of cortical myoclonus. Mov Disord. 2014;29:437–43.

    Article  PubMed  Google Scholar 

  70. Tijssen MA, Thom M, Ellison DW, Wilkins P, Barnes D, Thompson PD, Brown P. Cortical myoclonus and cerebellar pathology. Neurology. 2000;54:1350–6.

    Article  CAS  PubMed  Google Scholar 

  71. Defebvre L. Myoclonus and extrapyramidal diseases. Neurophysiol Clin. 2006;36:319–25.

    Article  CAS  PubMed  Google Scholar 

  72. van der Salm SM, Tijssen MA, Koelman JH, van Rootselaar AF. The bereitschaftspotential in jerky movement disorders. J Neurol Neurosurg Psychiatry. 2012;83:1162–7.

    Article  PubMed  Google Scholar 

  73. Gupta A, Lang AE. Psychogenic movement disorders. Curr Opin Neurol. 2009;22:430–6.

    Article  PubMed  Google Scholar 

  74. Frucht SJ, Houghton WC, Bordelon Y, Greene PE, Louis ED. A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor. Neurology. 2005;65:1967–9.

    Article  CAS  PubMed  Google Scholar 

  75. Arpesella R, Dallocchio C, Arbasino C, Imberti R, Martinotti R, Frucht SJ. A patient with intractable posthypoxic myoclonus (Lance-Adams syndrome) treated with sodium oxybate. Anaesth Intensive Care. 2009;37:314–8.

    CAS  PubMed  Google Scholar 

  76. Awaad Y, Tayem H, Elgamal A, Coyne MF. Treatment of childhood myoclonus with botulinum toxin type A. J Child Neurol. 1999;14:781–6.

    Article  CAS  PubMed  Google Scholar 

  77. Priori A, Bertolasi L, Pesenti A, Cappellari A, Barbieri S. gamma-hydroxybutyric acid for alcohol-sensitive myoclonus with dystonia. Neurology. 2000;54:1706.

    Article  CAS  PubMed  Google Scholar 

  78. Azoulay-Zyss J, Roze E, Welter ML, Navarro S, Yelnik J, Clot F, Bardinet E, Karachi C, Dormont D, Galanaud D, Pidoux B, Cornu P, Vidailhet M, Grabli D. Bilateral deep brain stimulation of the pallidum for myoclonus-dystonia due to epsilon-sarcoglycan mutations: a pilot study. Arch Neurol. 2011;68:94–8.

    Article  PubMed  Google Scholar 

  79. Striano P, Manganelli F, Boccella P, Perretti A, Striano S. Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. Mov Disord. 2005;20:1610–4.

    Article  PubMed  Google Scholar 

  80. Van Woert MH. Myoclonus and L-5-hydroxytryptophan (L-5HTP). Prog Clin Biol Res. 1983;127:43–52.

    PubMed  Google Scholar 

  81. Obeso JA, Rothwell JC, Quinn NP, Lang AE, Artieda J, Marsden CD. Lisuride in the treatment of myoclonus. Adv Neurol. 1986;43:191–6.

    CAS  PubMed  Google Scholar 

  82. Mineyko A, Whiting S, Graham GE. Hyperekplexia: treatment of a severe phenotype and review of the literature. Can J Neurol Sci. 2011;38:411–6.

    Article  PubMed  Google Scholar 

  83. Frucht SJ, Bordelon Y, Houghton WH, Reardan D. A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders. Mov Disord. 2005;20:1330–7.

    Article  PubMed  Google Scholar 

  84. Luciano AY, Jinnah HA, Pfeiffer RF, Truong DD, Nance MA, LeDoux MS. Treatment of myoclonus-dystonia syndrome with tetrabenazine. Parkinsonism Relat Disord. 2014;20:1423–6.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Rughani AI, Lozano AM. Surgical treatment of myoclonus dystonia syndrome. Mov Disord. 2013;28:282–7.

    Article  PubMed  Google Scholar 

  86. Sanger TD, Chen D, Fehlings DL, et al. Definition and classification of hyperkinetic movements in childhood. Mov Disord. 2010;25:1538–49.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Walker RH. Thoughts on selected movement disorder terminology and a plea for clarity. Tremor Other Hyperkinet Mov (N Y). 2013;3. pii: tre-03-203-4656-2.

    Google Scholar 

  88. Postuma RB, Lang AE. Hemiballism: revisiting a classic disorder. Lancet Neurol. 2003;2:661–8.

    Article  PubMed  Google Scholar 

  89. Twardowsky AO, Paz JA, Pastorino AC, Jacob CM, Marques-Dias MJ, Silva CA. Chorea in a child with Churg-Strauss syndrome. Acta Reumatol Port. 2010;35:72–5.

    PubMed  Google Scholar 

  90. Okanishi T, Enoki H. Transient subcortical high-signal lesions in Kawasaki syndrome. Pediatr Neurol. 2012;47:295–8.

    Article  PubMed  Google Scholar 

  91. Spagnoli C, Cantalupo G, Piccolo B, Cerasti D, Pisani F. Unusual trigeminal autonomic pain heralding hemichorea due to zoster sine Herpete vasculopathy. Pediatr Neurol. 2013;49:205–8.

    Article  PubMed  Google Scholar 

  92. Bhagwat NM, Joshi AS, Rao G, Varthakavi PK. Uncontrolled hyperglycaemia: a reversible cause of hemichorea-hemiballismus. BMJ Case Rep. 2013. pii: bcr2013010229. doi:10.1136/bcr-2013-010229.

    Google Scholar 

  93. Cherian A, Thomas B, Baheti NN, Chemmanam T, Kesavadas C. Concepts and controversies in nonketotic hyperglycemia-induced hemichorea: further evidence from susceptibility-weighted MR imaging. J Magn Reson Imaging. 2009;29:699–703.

    Article  PubMed  Google Scholar 

  94. Ahlskog JE, Nishino H, Evidente VG, Tulloch JW, Forbes GS, Caviness JN, Gwinn-Hardy KA. Persistent chorea triggered by hyperglycemic crisis in diabetics. Mov Disord. 2001;16:890–8.

    Article  CAS  PubMed  Google Scholar 

  95. Sporer B, Linke R, Seelos K, Paul R, Klopstock T, Pfister HW. HIV-induced chorea: evidence for basal ganglia dysregulation by SPECT. J Neurol. 2005;252:356–8.

    Article  CAS  PubMed  Google Scholar 

  96. Cosentino C, Vélez M, Torres L, Garcia HH. Neurocysticercosis-induced hemichorea. Mov Disord. 2006;21:286–7.

    Article  PubMed  Google Scholar 

  97. Ozer F, Meral H, Aydemir T, Ozturk O. Hemiballism-Hemichorea in presentation of cranial tuberculoma. Mov Disord. 2006;21:1293–4.

    Article  PubMed  Google Scholar 

  98. Patankar AP. Hemi-chorea: an unusual presentation of brainstem glioma. Br J Neurosurg. 2013;27:256–8.

    Article  CAS  PubMed  Google Scholar 

  99. Ząbek M, Sobstyl M, Dzierzęcki S, Górecki W, Jakuciński M. Right hemichorea treated successfully by surgical removal of a left putaminal cavernous angioma. Clin Neurol Neurosurg. 2013;115:844–6.

    Article  PubMed  Google Scholar 

  100. Xie T, Awad I, Kang UJ, Warnke P. DBS reduced hemichorea associated with a developmental venous anomaly and microbleeding in STN. Neurology. 2014;82:636–7.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Young VE, Pickett G, Richardson PL, Leach P. Choreathetoid movement as an unusual presentation of subdural haematoma. Acta Neurochir (Wien). 2008;150:733–5.

    Article  CAS  Google Scholar 

  102. Williams KA, Swedo SE. Post-infectious autoimmune disorders: Sydenham’s chorea, PANDAS and beyond. Brain Res. 2015;1617:144–54.

    Article  CAS  PubMed  Google Scholar 

  103. Cardoso F. Sydenham’s chorea. Handb Clin Neurol. 2011;100:221–9.

    Article  PubMed  Google Scholar 

  104. Zöller B, Li X, Sundquist J, Sundquist K. Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. PLoS One. 2012;7:e33442.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Beato R, Siqueira CF, Marroni BJ, Boanova LG, de Lima CF, Maia DP, Nattan M, Cardoso F. Brain SPECT in Sydenham’s chorea in remission. Mov Disord. 2014;29:256–8.

    Article  PubMed  Google Scholar 

  106. Ben-Pazi H, Stoner JA, Cunningham MW. Dopamine receptor autoantibodies correlate with symptoms in Sydenham’s chorea. PLoS One. 2013;8, e73516.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Maia DP, Fonseca PG, Camargos ST, Pfannes C, Cunningham MC, Cardoso F. Pregnancy in patients with Sydenham’s Chorea. Parkinsonism Relat Disord. 2012;18:458–61.

    Article  PubMed  Google Scholar 

  108. O’Toole O, Lennon VA, Ahlskog JE, Matsumoto JY, Pittock SJ, Bower J, Fealey R, Lachance DH, McKeon A. Autoimmune chorea in adults. Neurology. 2013;80:1133–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Reiner P, Galanaud D, Leroux G, Vidailhet M, Haroche J, du Huong LT, Francès C, Papo T, de Gennes C, Musset L, Wechsler B, Amoura Z, Piette JC, Costedoat-Chalumeau N. Long-term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies. Mov Disord. 2011;26:2422–7.

    Article  PubMed  Google Scholar 

  110. Baizabal-Carvallo JF, Bonnet C, Jankovic J. Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. J Neural Transm. 2013;120:1579–89.

    Article  CAS  PubMed  Google Scholar 

  111. Leblicq C, Duval M, Carmant L, Van Vliet G, Alos N. Rising serum thyroxine levels and chorea in graves’ disease. Pediatrics. 2013;131:e616–9.

    Article  PubMed  Google Scholar 

  112. Isaacs JD, Rakshi J, Baker R, Brooks DJ, Warrens AN. Chorea associated with thyroxine replacement therapy. Mov Disord. 2005;20:1656–7.

    Article  PubMed  Google Scholar 

  113. Vela L, Sfakianakis GN, Heros D, Koller W, Singer C. Chorea and contraceptives: case report with pet study and review of the literature. Mov Disord. 2004;19:349–52.

    Article  CAS  PubMed  Google Scholar 

  114. Zesiewicz TA, Sullivan KL. Drug-induced hyperkinetic movement disorders by nonneuroleptic agents. Handb Clin Neurol. 2011;100:347–63.

    Article  PubMed  Google Scholar 

  115. Giordano A, Amboni M, Tessitore A. Valproate-induced generalized choreoathetosis. Mov Disord Clin Pract. 2014;1:271–2.

    Article  Google Scholar 

  116. Zesiewicz TA, Shimberg WR, Hauser RA, Robinson W, Wilson MC, Sullivan KL. Chorea as a side effect of gabapentin (Neurontin) in a patient with complex regional pain syndrome Type 1. Clin Rheumatol. 2008;27:389–90.

    Article  PubMed  Google Scholar 

  117. van der Plas AA, van Rijn MA, van Hilten JJ. Baclofen-induced chorea in complex regional pain syndrome-related dystonia. Mov Disord. 2010;25:959–60.

    Article  PubMed  Google Scholar 

  118. Miyasaki JM. Chorea caused by toxins. Handb Clin Neurol. 2011;100:335–46.

    Article  PubMed  Google Scholar 

  119. Kamath S, Bajaj N. Crack dancing in the United Kingdom: apropos a video case presentation. Mov Disord. 2007;22:1190–1.

    Article  PubMed  Google Scholar 

  120. Walker RH. Further evidence for celiac disease-associated chorea. Tremor Other Hyperkinet Mov (N Y). 2011;1. pii: tre-01-32-96-3.

    Google Scholar 

  121. Hacohen Y, Deiva K, Pettingill P, Waters P, Siddiqui A, Chretien P, Menson E, Lin JP, Tardieu M, Vincent A, Lim MJ. N-methyl-D-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse. Mov Disord. 2014;29:90–6.

    Article  CAS  PubMed  Google Scholar 

  122. Mohammad SS, Sinclair K, Pillai S, Merheb V, Aumann TD, Gill D, Dale RC, Brilot F. Herpes simplex encephalitis relapse with chorea is associated with autoantibodies to N-Methyl-D-aspartate receptor or dopamine-2 receptor. Mov Disord. 2014;29:117–22.

    Article  CAS  PubMed  Google Scholar 

  123. Tofaris GK, Irani SR, Cheeran BJ, Baker IW, Cader ZM, Vincent A. Immunotherapy-responsive chorea as the presenting feature of LGI1-antibody encephalitis. Neurology. 2012;79:195–6.

    Article  PubMed  PubMed Central  Google Scholar 

  124. Ramdhani RA, Frucht SJ. Isolated chorea associated with LGI1 antibody. Tremor Other Hyperkinet Mov (N Y). 2014;4. pii: tre-04-213-4821-1. doi:10.7916/D8MG7MFC.

  125. Kruer MC, Hoeftberger R, Lim KY, Coryell JC, Svoboda MD, Woltjer RL, Dalmau J. Aggressive course in encephalitis with opsoclonus, ataxia, chorea, and seizures: the first pediatric case of γ-aminobutyric acid type B receptor autoimmunity. JAMA Neurol. 2014;71:620–3.

    Article  PubMed  PubMed Central  Google Scholar 

  126. Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol. 2014;13:575–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Jung S, Hwnag SH, Kang SY, Kwon SB. Bilateral choreiform movements induced by excessive sucrose ingestion. Mov Disord. 2009;24:1247–9.

    Article  PubMed  Google Scholar 

  128. Wszolek ZK, Baba Y, Mackenzie IR, Uitti RJ, Strongosky AJ, Broderick DF, Baker MC, Melquist S, Hutton ML, Tsuboi Y, Allanson JE, Carr J, Kumar A, Calne SM, Miklossy J, McGeer PL, Calne DB, Stoessl AJ. Autosomal dominant dystonia-plus with cerebral calcifications. Neurology. 2006;67:620–5.

    Article  CAS  PubMed  Google Scholar 

  129. Yaltho TC, Schiess MC, Furr-Stimming E. Acute bilateral basal ganglia lesions and chorea in a diabetic-uremic patient on dialysis. Arch Neurol. 2010;67:246.

    Article  PubMed  Google Scholar 

  130. Kumar H, Masiowski P, Jog M. Chorea in the elderly with mutation positive polycythemia vera: a case report. Can J Neurol Sci. 2009;36:370–2.

    Article  PubMed  Google Scholar 

  131. Severs M, Boelens HM, Diraoui SB, Schuur J. Chorea and a frontal lobe syndrome: a rare neurological presentation of polycythemia vera; a case report. J Am Geriatr Soc. 2012;60:589–90.

    Article  PubMed  Google Scholar 

  132. Venkatesan EP, Ramadoss K, Balakrishnan R, Prakash B. Essential thrombocythemia: rare cause of chorea. Ann Indian Acad Neurol. 2014;17:106–7.

    Article  PubMed  PubMed Central  Google Scholar 

  133. Dale RC, Singh H, Troedson C, Pillai S, Gaikiwari S, Kozlowska K. A prospective study of acute movement disorders in children. Dev Med Child Neurol. 2010;52:739–48.

    Article  PubMed  Google Scholar 

  134. Ahn ES, Scott RM, Robertson Jr RL, Smith ER. Chorea in the clinical presentation of moyamoya disease: results of surgical revascularization and a proposed clinicopathological correlation. J Neurosurg Pediatr. 2013;11:313–9.

    Article  PubMed  Google Scholar 

  135. Wild EJ, Mudanohwo EE, Sweeney MG, Schneider SA, Beck J, Bhatia KP, Rossor MN, Davis MB, Tabrizi SJ. Huntington’s disease phenocopies are clinically and genetically heterogeneous. Mov Disord. 2008;23:716–20.

    Article  PubMed  Google Scholar 

  136. Cardoso F. Differential diagnosis of Huntington’s disease: what the clinician should know. Neurodegener Dis Manag. 2014;4:67–72.

    Article  PubMed  Google Scholar 

  137. Gras D, Jonard L, Roze E, Chantot-Bastaraud S, Koht J, Motte J, Rodriguez D, Louha M, Caubel I, Kemlin I, Lion-François L, Goizet C, Guillot L, Moutard ML, Epaud R, Héron B, Charles P, Tallot M, Camuzat A, Durr A, Polak M, Devos D, Sanlaville D, Vuillaume I, Billette de Villemeur T, Vidailhet M, Doummar D. Benign hereditary chorea: phenotype, prognosis, therapeutic outcome and long term follow-up in a large series with new mutations in the TITF1/NKX2-1 gene. J Neurol Neurosurg Psychiatry. 2012;83:956–62.

    Article  PubMed  Google Scholar 

  138. Ferlazzo E, Gasparini S, Gambardella A, Labate A, Cianci V, Cherubini A, Lanza P, Quattrone A, Aguglia U. Unilateral basal ganglia atrophy in a patient with tuberous sclerosis complex and hemichorea. Mov Disord. 2012;27:458–60.

    Article  PubMed  Google Scholar 

  139. McNeill A, Pandolfo M, Kuhn J, Shang H, Miyajima H. The neurological presentation of ceruloplasmin gene mutations. Eur Neurol. 2008;60:200–5.

    Article  PubMed  Google Scholar 

  140. Lee JH, Berkowitz RJ, Choi BJ. Oral self-mutilation in the Lesch-Nyhan syndrome. ASDC J Dent Child. 2002;69:66–9.

    PubMed  Google Scholar 

  141. Przekop A, Sanger TD. Birth-related syndromes of athetosis and kernicterus. Handb Clin Neurol. 2011;100:387–95.

    Article  PubMed  Google Scholar 

  142. Quarrell OW, Nance MA, Nopoulos P, Paulsen JS, Smith JA, Squitieri F. Managing juvenile Huntington’s disease. Neurodegener Dis Manag. 2013;3. doi:10.2217/nmt.13.18.

    Google Scholar 

  143. Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, Scahill RI, Leavitt BR, Stout JC, Paulsen JS, Reilmann R, Unschuld PG, Wexler A, Margolis RL, Tabrizi SJ. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10:204–16.

    Article  CAS  PubMed  Google Scholar 

  144. Papoutsi M, Labuschagne I, Tabrizi SJ, Stout JC. The cognitive burden in Huntington’s disease: pathology, phenotype, and mechanisms of compensation. Mov Disord. 2014;29:673–83.

    Article  PubMed  Google Scholar 

  145. Walker RH. Update on the Non-Huntington’s disease choreas with comments on the current nomenclature. Tremor Other Hyperkinet Mov (N Y). 2012;2. pii: tre-02-49-211-1.

    Google Scholar 

  146. Martino D, Stamelou M, Bhatia KP. The differential diagnosis of Huntington’s disease-like syndromes: ‘red flags’ for the clinician. J Neurol Neurosurg Psychiatry. 2013;84:650–6.

    Article  PubMed  Google Scholar 

  147. Hensmann Moss DJ, Poulter M, Beck J, Hehir J, Polke JM, Campbell T, Adamson G, Mudanohwo E, McColgan P, Haworth A, Wild EJ, Sweeney MG, Houlden H, Mead S, Tabrizi SJ. C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology. 2014;82:292–9.

    Article  CAS  Google Scholar 

  148. Lee WW, Kim SY, Kim JY, Kim HJ, Park SS, Jeon BS. Extrapyramidal signs are a common feature of spinocerebellar ataxia type 17. Neurology. 2009;73:1708–9.

    Article  PubMed  Google Scholar 

  149. Fischer CA, Licht EA, Mendez MF. The neuropsychiatric manifestations of Huntington’s disease-like 2. J Neuropsychiatry Clin Neurosci. 2012;24:489–92.

    Article  PubMed  Google Scholar 

  150. Jung HH, Danek A, Walker RH. Neuroacanthocytosis syndromes. Orphanet J Rare Dis. 2011;6:68.

    Article  PubMed  PubMed Central  Google Scholar 

  151. Schneider SA, Lang AE, Moro E, Bader B, Danek A, Bhatia KP. Characteristic head drops and axial extension in advanced chorea-acanthocytosis. Mov Disord. 2010;25:1487–91.

    Article  PubMed  Google Scholar 

  152. Morgante F, Girlanda P, Martino D. Head drop in Huntington disease: insights into the pathophysiology. Neurology. 2013;81:769–70.

    Article  PubMed  Google Scholar 

  153. Wardle M, Morris HR, Robertson NP. Clinical and genetic characteristics of non-Asian dentatorubral-pallidoluysian atrophy: a systematic review. Mov Disord. 2009;24:1636–40.

    Article  PubMed  Google Scholar 

  154. Wong JC, Armstrong MJ, Lang AE, Hazrati LN. Clinicopathological review of pallidonigroluysian atrophy. Mov Disord. 2013;28:274–81.

    Article  PubMed  Google Scholar 

  155. Crompton DE, Chinnery PF, Bates D, Walls TJ, Jackson MJ, Curtis AJ, Burn J. Spectrum of movement disorders in neuroferritinopathy. Mov Disord. 2005;20:95–9.

    Article  PubMed  Google Scholar 

  156. Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA. Evidence-based guideline: treatment of tardive syndromes. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81:463–9.

    Article  PubMed  Google Scholar 

  157. Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990;147:445–51.

    Article  CAS  PubMed  Google Scholar 

  158. Zhang WF, Tan YL, Zhang XY, Chan RC, Wu HR, Zhou DF. Extract of ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72:615–21.

    Article  PubMed  Google Scholar 

  159. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999;156:1279–81.

    CAS  PubMed  Google Scholar 

  160. Angus S, Sugars J, Boltezar R, Koskewich S, Schneider NM. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1997;17:88–91.

    Article  CAS  PubMed  Google Scholar 

  161. Factor SA. Propranolol therapy for tardive dyskinesia revisited. Mov Disord. 2012;27:1703.

    Article  PubMed  Google Scholar 

  162. Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ, Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence based-review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:983–95.

    Article  CAS  PubMed  Google Scholar 

  163. Nicolas G, Richard AC, Pottier C, Verny C, Durif F, Roze E, Favrole P, Rudolf G, Anheim M, Tranchant C, Frebourg T, Campion D, Hannequin D. Overall mutational spectrum of SLC20A2, PDGFB and PDGFRB in idiopathic basal ganglia calcification. Neurogenetics. 2014;15:215–6.

    Article  PubMed  Google Scholar 

  164. Jog MS, Lang AE. Chronic acquired hepatocerebral degeneration: case reports and new insights. Mov Disord. 1995;10:714–22.

    Article  CAS  PubMed  Google Scholar 

  165. Paucar M, Xiang F, Moore R, Walker R, Winnberg E, Svenningsson P. Genotype-phenotype analysis in inherited prion disease with eight octapeptide repeat insertional mutation. Prion. 2013;7.

    Google Scholar 

  166. McKee D, Talbot P. Chorea as a presenting feature of variant Creutzfeldt-Jakob disease. Mov Disord. 2003;18:837–8.

    Article  PubMed  Google Scholar 

  167. Yoshida Y, Nunomura J, Shimohata T, Nanjo H, Miyata H. Benign hereditary chorea 2: pathological findings in an autopsy case. Neuropathology. 2012;32:557–65.

    Article  PubMed  Google Scholar 

  168. Prashanth LK, Fox S, Meissner WG. l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment. Int Rev Neurobiol. 2011;98:31–54.

    Article  CAS  PubMed  Google Scholar 

  169. Fabbrini G, Defazio G, Colosimo C, Suppa A, Bloise M, Berardelli A. Onset and spread of dyskinesias and motor symptoms in Parkinson’s disease. Mov Disord. 2009;24:2091–6.

    Article  PubMed  Google Scholar 

  170. Aquino CC, Lang AE. Tardive dyskinesia syndromes: current concepts. Parkinsonism Relat Disord. 2014;20:S113–7.

    Article  PubMed  Google Scholar 

  171. Anheim M, Lagha-Boukbiza O, Fleury-Lesaunier MC, Valenti-Hirsch MP, Hirsch E, Gervais-Bernard H, Broussolle E, Thobois S, Vanier MT, Latour P, Tranchant C. Heterogeneity and frequency of movement disorders in juvenile and adult-onset Niemann-Pick C disease. J Neurol. 2014;261:174–9.

    Article  PubMed  Google Scholar 

  172. Martinelli P, Rizzo G, Scaglione C, Capellari S. Neurosyphilis orofacial dyskinesia: the candy sign. Mov Disord. 2013;28:246–7.

    Article  PubMed  Google Scholar 

  173. Fasano A, Bentivoglio AR. Tetrabenazine. Expert Opin Pharmacother. 2009;10:2883–96.

    Article  CAS  PubMed  Google Scholar 

  174. Walker KG, Wilmshurst JM. An update on the treatment of Sydenham’s chorea: the evidence for established and evolving interventions. Ther Adv Neurol Disord. 2010;3:301–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  175. Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST, Taubert KA. Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic fever, endocarditis, and Kawasaki disease committee of the council on cardiovascular disease in the young, the interdisciplinary council on functional genomics and translational biology, and the interdisciplinary council on quality of care and outcomes research: endorsed by the American Academy of pediatrics. Circulation. 2009;119:1541–51.

    Article  CAS  PubMed  Google Scholar 

  176. Peluso S, Antenora A, De Rosa A, Roca A, Maddaluno G, Brescia Morra V, De Michele G. Antiphospholipid-related chorea. Front Neurol. 2012;3:150.

    Article  PubMed  PubMed Central  Google Scholar 

  177. Rosenfeld MR, Dalmau J. Anti-NMDA-receptor encephalitis and other synaptic autoimmune disorders. Curr Treat Options Neurol. 2011;13:324–32.

    Article  PubMed  PubMed Central  Google Scholar 

  178. Edwards TC, Zrinzo L, Limousin P, Foltynie T. Deep brain stimulation in the treatment of chorea. Mov Disord. 2012;27:357–63.

    Article  PubMed  Google Scholar 

  179. Fasano A, Mazzone P, Piano C, Quaranta D, Soleti F, Bentivoglio AR. GPi-DBS in Huntington’s disease: results on motor function and cognition in a 72-year-old case. Mov Disord. 2008;23:1289–92.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurology Department, King’s College Hospital NHS Foundation Trust, London, UK

    Davide Martino MD, PhD (Consultant Neurologist and Honorary Senior Lecturer)

  2. James J. and Joan A. Gardner Center for Parkinson’s Disease and Movement Disorders, University of Cincinnati, Cincinnati, Ohio, USA

    Alberto J. Espay MD, MSc (Associate Professor of Neurology)

  3. Division of Neurology, University of Toronto Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson’s Disease Toronto Western Hospital, UHN, Toronto, Ontario, Canada

    Alfonso Fasano MD, PhD (Associate Professor of Medicine)

  4. Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy

    Francesca Morgante MD, PhD (Assistant Professor Neurology)

Authors
  1. Davide Martino MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alberto J. Espay MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alfonso Fasano MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francesca Morgante MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Martino, D., Espay, A.J., Fasano, A., Morgante, F. (2016). Rapid Intermittent Involuntary Movements. In: Disorders of Movement. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-48468-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-48468-5_7

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-48466-1

  • Online ISBN: 978-3-662-48468-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation